Critical Reviews in Oncology/Hematology Journal Citation Rate 2026
1040-8428
eISSN 1879-0461
Elsevier BV
NL
Q1 Quartile Established Impact
About Critical Reviews in Oncology/Hematology
Critical Reviews in Oncology/Hematology (CRO) is a peer-reviewed academic journal covering Cancer Immunotherapy and Biomarkers and Diverse Scientific and Economic Studies, published by Elsevier BV in NL, catalogued under ISSN 1040-8428 (e-ISSN 1879-0461). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 4.62 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$3690 USD).
Critical Reviews in Oncology/Hematology Citation Rate 2026 — In Context
Critical Reviews in Oncology/Hematology has a 2025 2-Year Citation Rate (OpenAlex) of 4.62, placing it in the Q1 quartile within the Cancer Immunotherapy and Biomarkers research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Critical Reviews in Oncology/Hematology operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Critical Reviews in Oncology/Hematology should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Critical Reviews in Oncology/Hematology against similar journals in the field, use our journal comparison tool.
Submission Tips for Critical Reviews in Oncology/Hematology
- Budget $3690 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers Cancer Immunotherapy and Biomarkers, Diverse Scientific and Economic Studies, Educational Robotics and Engineering. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Critical Reviews in … Compares
Compared against 93 journals in the same research areas.
| ISSN (Print) | 1040-8428 |
|---|---|
| ISSN (Online) | 1879-0461 |
| Publisher | Elsevier BV |
| Country | Netherlands |
| APC / Cost | $3690 USD |
In-depth profile & metrics
Critical Reviews in Oncology/Hematology is published by Elsevier BV and based in Netherlands. It runs on a subscription or hybrid model with an article-processing charge of USD 3690.
In our subject taxonomy, Critical Reviews in Oncology/Hematology is classified under Cancer Immunotherapy and Biomarkers, Diverse Scientific and Economic Studies, Educational Robotics and Engineering and Human auditory perception and evaluation.
Critical Reviews in Oncology/Hematology is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 4.620.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Critical Reviews in Oncology/Hematology
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 4.620 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Critical Reviews in Oncology/… against similar publications in its field:
Related Journals in Your Field
-
American Political Science Review Cambridge University Press IF 56.90
-
Advanced Drug Delivery Reviews Elsevier BV IF 12.22
-
Pharmacology & Therapeutics Elsevier BV IF 10.38
-
Business Horizons Elsevier BV IF 8.87
-
Trends in Pharmacological Sciences Elsevier BV IF 8.53
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S185233701
Get weekly updates for Cancer Immunotherapy and Biomarkers journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.